$30 mil is the cost of B-ABSSSI Phase 3 trials (th
Post# of 72435
Yes, they don't need to pay the whole lump sum of that $30 mil upfront to the CRO
Leo can raise money as it goes .
But why would he want to risk such a pivotal trial by not having the money fully secured for the trial since he already know the budget?
Aspire may not necessarily want to do a deal with CTIX if poor financial market circumstances arises.
Even NNVC has about $40 mil in the bank when they uplisted to AMEX 2 years ago and they don't even have any clinical trials conducted!